Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • May 30, 2007

166_ip_2007-05-30_6a9dbd81-6cb5-4497-991e-70e8cb774952.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Health Care Worldwide

Bank of America, 2007 Health Care Conference, May 30, 2007

Fresenius

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Fresenius – Achieving Profitable Growth in Attractive Health Care Segments

Fresenius Medical Care is fully consolidated in the financial statements of Fresenius AG

Fresenius Group: Excellent Start into 2007

Fresenius Kabi: Continued Strong Organic Sales Growth and EBIT Margin Expansion

  • Focus on organic growth and on selective acquisitions to expand regional presence and product portfolio
  • Introduce new production technologies and processes to further gain efficiencies and optimize cost structures
  • Outlook 2007:
S
(
)
l
h
i
t
a
e
s
g
r
o
w
o
r
g
a
n
c
:		 6
8
%
–
E
B
I
T
i
m
a
r
g
n
:		 1
6
0
1
6
%
5
–

Fresenius ProServe: Significant German Hospital Privatization Opportunity

  • Germany is Europe's largest hospital market (> € 60 billion market size)
  • Only 11 % of German acute hospital beds managed by private operators
  • Market provides value-creation opportunity for efficient players with superior medical quality

Outlook 2007: Sales growth (organic): 2 – 3 % EBIT:160 – 170 €m

Fresenius Group : Positive Outlook 2007 Confirmed

Guidance

R
h
t
e
e
n
e
g
r
o
v
u
w		 8
1
0
%
–
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y
N
i
h
t
t
e
n
c
o
m
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 2
0
2
%
5
–
C
a
p
e
x		 6
0
0
0
0
€
7
m
–

Attachments

Fresenius Kabi: Sales Q1 2007 – In Line with Guidance

€
m		 Q
1
2
0
0
7		 Q
1
2
0
0
6		 O
i
r
g
a
n
c
G
h
t
r
o
w
S
T
l
l
t
o
a
a
e
s		 4
8
3		 4
6
6		 6
%
B
P
d
S
t
t
y
r
o
u
c
e
g
m
e
n
:
f
I
i
T
h
n
u
s
o
n
e
r
a
p
y		 2
6
2		 2
5
7		 4
%
C
l
i
i
l
N
i
i
t
t
n
c
a
r
o
n
u		 1
9
4		 1
8
0		 1
0
%
T
f
i
T
h
l
r
a
n
s
u
s
o
n
e
c
n
o
o
g
y		 2
7		 2
9		 %
5
-

Fresenius Kabi: Organic Sales Growth of 6 %

S
l
h
l
i
t
a
e
s
g
r
o
w
a
n
a
y
s
s		 S
R
i
l
l
e
g
o
n
a
a
e
s		 Q
1
2
0
0
7
€
m		 Q
1
2
0
0
6
€
m		 G
h
t
r
o
w		 O
i
r
g
a
n
c
G
h
t
r
o
w
i
%
n
y		 oy Q
1
2
0
0
7
s		 l
4
8
3
€
a
e
s
m
:		 G
e
r
m
a
n
y		 1
0
6		 1
0
8		 2
%
-		 1
%
-
3
%
-		 E
G
r
o
p
e
u
e
x
e
r
m
a
n
y		 2
3
0		 2
1
9		 %
5		 %
5
1
%
+		 A
i
P
i
f
i
s
a
a
c
c
-		 6
9		 5
9		 1
7
%		 2
2
%
L
i
A
i
t
a
n
m
e
r
c
a		 3
0		 3
0		 0
%		 %
7
6
%
+		 4
%
+		 R
W
o		 4
8		 0
5		 4
%
-		 8
%
O
i
r
g
a
n
c
G
h
t
r
o
w		 F
X		 A
i
c
q
u
i
i
t
s
o
n		 R
d
t
e
p
o
r
e		 T
l
l
t
o
a
s
a
e
s		 4
8
3		 4
6
6		 4
%		 6
%

Fresenius Kabi: Excellent EBIT Development

€
m		 Q
1
2
0
0
7		 Q
1
2
0
0
6		 C
h
a
n
g
e
E
B
I
T
E
B
I
T
i
m
a
r
g
n		 7
7
1
5
9
%		 6
8
1
4
6
%		 1
3
%
E
B
I
T
b
R
i
y
e
g
o
n
:
E
r
o
p
e
ƒ
u
E
B
I
T
i
m
a
r
g
n		 2
7
2
1.
4
%		 6
2
1
9
0
%		 1
6
%
I
i
l
t
t
n
e
r
n
a
o
n
a
ƒ
E
B
I
T
i
m
a
r
g
n		 2
2
1
5.
0
%		 2
1
1
5
1
%		 %
5
C
d
C
R
&
D
t
t
o
r
p
o
r
a
e
a
n
o
r
p
o
r
a
e
ƒ		 1
7
-		 1
5
-		 1
3
%
-
N
i
t
e
n
c
o
m
e		 4
2		 2
6		 6
2
%

Fresenius ProServe: Accomplishments

  • Strong sales and earnings development
  • Continued growth strategy in the German hospital market:
  • Acquisition of three hospitals with ~ 500 beds
  • Option exercised to acquire remaining 40 % HUMAINE shares
  • Divestiture of Pharmaplan finalized
  • Pharmatec: agreement to sell business to Bosch group; closing expected end of H1 2007

Fresenius ProServe: Very Good Sales Growth in Q1 2007

€
m		 Q
1
2
0
0
7		 Q
1
2
0
0
6		 G
h
t
r
o
w		 O
i
r
g
a
n
c
G
h
t
r
o
w
S
l
a
e
s		 5
2
1		 4
7
6		 9
%		 3
%
S
l
b
D
i
i
i
a
e
s
y
v
s
o
n
:
O
H
i
l
i
t
t
(
O
S
)
H
E
L
I
o
s
p
a
p
e
r
a
o
n
s		 4
3
9		 3
8
3		 1
%
5		 3
%
S
E
i
i
i
f
h
i
l
t
n
g
n
e
e
r
n
g
+
e
r
c
e
s
o
r
o
s
p
a
s
v
(
)
V
A
M
E
D
P
h
t
+
a
r
m
a
e
c		 8
2		 *
9
3		 1
2
%
-		 2
%
O
d
i
k
E
i
i
b
i
t
r
e
r
n
a
e
n
g
n
e
e
r
n
g
u
s
n
e
s
s		 8
7		 6
6
*		 1
8
%		 4
4
%
*
I
lu
d
i
P
h
l
n
c
n
g
a
r
m
a
p
a
n

Fresenius ProServe: Strong EBIT Development

€
m		 Q
1
2
0
0
7		 Q
1
2
0
0
6		 G
h
t
r
o
w
E
B
I
T
E
B
I
T
i
m
a
r
g
n		 3
6
6
9
%		 3
0
6
3
%		 2
0
%
i
i
i
E
B
I
T
b
D
s
o
n
y
v
:
H
i
l
i
t
t
ƒ
o
s
p
a
o
p
e
r
a
o
n
s
E
B
I
T
i
m
a
r
g
n		 3
2
7
3
%		 2
7
0
%
7		 1
9
%
S
f
E
i
i
i
h
i
l
t
n
g
n
e
e
r
n
g
+
e
r
v
c
e
s
o
r
o
s
p
a
s
ƒ
E
B
I
T
i
m
a
r
g
n		 5
6
1
%		 *
5
4
%
5		 -
C
t
t
o
r
p
o
r
a
e
c
o
s
s
ƒ		 1
-		 2
-		 -
*
I
lu
d
i
P
h
l
n
c
n
g
a
r
m
a
p
a
n

Fresenius Biotech: 2007 Accomplishments

Provided very encouraging results in malignant ascites from various cancers in March 2007

Survival data of the phase II/III study in malignant ascites for both strata to follow in Q2 2007

Partnering process for trifunctional antibodies in North America and Japan started

Group Financials Q1 2007

Fresenius Group: Impact of Currency Translation

Fresenius Group: Profit and Loss Statement

€
m		 Q
1
2
0
0
7		 Q
1
2
0
0
6		 C
h
a
l
t
a
c
a
u
t
r
a
e
s		 n
g
e
t
t
c
o
n
s
a
n
t
r
a
e
s		 R
k
e
m
a
r
s
S
l
a
e
s		 2
6
7
7
,		 2
3
8
8
,		 1
6
%
+		 2
2
%
+		 i
h
7
%
t
o
r
g
a
n
c
g
r
o
w
E
B
I
T		 3
8
0		 2
9
1		 3
1
%
+		 3
%
7
+		 S
E
B
I
T
i
t
1
3.
7
%
r
o
n
g
m
a
r
g
n
I
l
t
t
t
n
e
r
e
s
r
e
s
u		 9
5
-		 8
4
-		 1
3
%
-		 2
1
%
-		 C
I
f
R
G
i
i
i
f
t
t
m
p
a
c
o
a
c
q
s
o
n
r
o
m
u
Q
2
0
6
T
a
e
s
x		 1
0
3
-		 6
7
-		 3
6
%
-		 4
2
%
-		 3
6.
1
%
t
t
a
x
r
a
e
N
i
t
e
n
c
o
m
e		 9
3		 6
5		 4
3
%
+		 4
8
%
+		 Q
1
0
6
i
l.
1
1
€
i
t
n
c
m
o
n
e-
m
e
:
e
x
p
e
n
s
e
s
S
E
P
(
f
)
(
€
p
r
e
s
*
A
d
j
d
f
h
l
i
t
t
u
s
e
o
r
s
a
r
e
s
p		 )
0
6
0		 0
4
3
*		 4
0
%
+		 4
4
%
+

Fresenius Group: Cash Flow

€
m		 Q
1
2
0
0
7		 Q
1
2
0
0
6		 C
h
a
n
g
e
Y
Y
o		 R
k
e
m
a
r
s
C
f
h
l
a
s
o
w		 2
8
4		 2
1
8		 3
0
%
+		 S
i
h
t
t
r
o
n
g
e
a
r
n
n
g
s
g
r
o
w
C
h
i
k
i
i
l
t
a
n
g
e
n
o
r
n
g
c
a
p
a
w		 3 3
2
-		 --
O
C
i
h
f
l
t
p
e
r
a
n
g
a
s
o
w		 2
8
7		 1
8
6		 4
%
5
+		 M
i
1
0
4
%
a
r
g
n
:
C
(
)
t
a
p
e
x
n
e		 1
3
2
-		 9
5
-		 3
9
%
-		 I
i
i
h
t
t
t
n
v
e
s
n
g
n
o
g
r
o
w
C
h
f
l
a
s
o
w
(
b
f
i
i
i
d
d
i
i
d
d
)
t
e
o
r
e
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 1
5
5		 9
1		 7
0
%
+
(
)
A
i
i
i
t
t
c
q
u
s
o
n
s
n
e		 6
3
-		 3
2
9
0
-
,		 --
D
i
i
d
d
v
e
n
s		 4
-		 0 --
C
F
h
f
l
r
e
e
a
s
o
w
(
f
i
i
i
d
d
i
i
d
d
)
t
t
a
e
r
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 8
8		 3
1
9
9
-
,		 --

Fresenius Group: Debt and Interest Ratios

Financial Calender

August 2, 2007 Report on 1st half 2007 October 31, 2007 Report on 1st - 3rd quarters 2007

Contact

Birgit Grund SVP Investor Relations Fresenius AG

Telephone: +49 6172 608-2485 e-mail: [email protected]

Further information and current news: http://www.fresenius-ag.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.